AVE 0.00% 0.2¢ avecho biotechnology limited

financials have been released, page-51

  1. 564 Posts.
    lightbulb Created with Sketch. 1
    Wow, so now calling the company into question is considered a scare tactic?

    I don't assume the company will keep current cash burn rates, I think they'll burn more given the upcoming launch of cellucreme and Phase 2 oxy trials.

    Thanks for pointing out 'available for sale assets'. Interesting that POH stated their value at the time of contract signing. Why not tell us what they are worth today? Maybe because its worth $1.2m less?

    1.44m share times current PRPH price of $1.39 =$2.0m, or slightly less in AUD.

    Although presumably in the accounts they'll mark it as at Dec 31st that comes out to 1.44m * $1.20 =$1.7m in AUD terms.

    I too don't expect POH will have any issues as an ongoing concern or raising funds in the short term. My point is to demonstrate that contrary to the rosy projections given out on this forum, that POH is once again leaving it later than they should to get their funding in order and even then it is still not clear how funding will be secured for their longer term projects.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.